Gu Mi

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila et al. · The Lancet Oncology · 2019 · 275 citations · Full text

Medicine, Oncology, Pharmacology +16

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)

Hendrik‐Tobias Arkenau, Juan Martín-Liberal, Emiliano Calvo et al. · The Oncologist · 2018 · 168 citations · Full text

Medicine, Oncology, Pharmacology +17

Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)

Yung‐Jue Bang, Talia Golan, Laëtitia Dahan et al. · European Journal of Cancer · 2020 · 133 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC

Roy S. Herbst, Hendrik Tobias Arkenau, Johanna C. Bendell et al. · Journal of Thoracic Oncology · 2020 · 59 citations · Full text

Medicine, Oncology, Pharmacology +17

Length Bias Correction in Gene Ontology Enrichment Analysis Using Logistic Regression

Gu Mi, Yanming Di, Sarah Emerson et al. · PLoS ONE · 2012 · 43 citations · Full text

Life Sciences, Biostatistics, Molecular Biology +13